Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Patent
1995-03-24
1999-09-28
Ulm, John
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
514 2, 514 12, 5303891, 5303871, A61K 3816, A61K 39395
Patent
active
059584114
ABSTRACT:
The present invention relates to methods for preventing, suppressing or treating a CNS pathology characterized by a deleterious accumulation of extracellular matrix in a tissue by contacting the tissue with an agent that inhibits the extracellular matrix producing activity of TGF-.beta.. The methods can be used to prevent, suppress or treat scar formation in the CNS. Agents that are useful in the present methods include neutralizing anti-TGF-.beta. antibodies, Arg-Gly-Asp-containing peptides, decorin and its functional equivalents such as biglycan, and TGF-.beta. antagonists. The present invention further provides methods for preventing, suppressing or treating a CNS pathology characterized by the insufficient accumulation of extracellular matrix. Agents that enhance the production of extracellular matrix, such as TGF-.beta., can be used in such methods. Finally, the present invention provides pharmaceutical compositions containing these agents, which can be administered to patients to inhibit or enhance the production of extracellular matrix in the CNS.
REFERENCES:
patent: 5583103 (1996-12-01), Ruoslahti et al.
Kengaku et al. (1991) Dev. Brain Res. 61, 281-284.
Shah et al. 1992 Faucet 339: 213-214.
Sammuels et al 1989 Am. J. Pathol. 134 (4): 895.
Yamaguchi et al. 1990 Nature 346:281.
Border et al 1990 Cell Diff. Devel. 32: 425-432.
Logan et al., "CF 313--In Vivo Effects of Growth Factor Agonists and Antagonists on Mammalian CNS Injury Responses" Journal of Cellular Biochemistry Abstracts, 20th Annual Meeting, Supplement 15F, Apr. 1, 1991-Apr. 7, 1991.
Nichols et al., "Increases in Transforming Growth Factor-.beta. mRNA in Hippocampus During Response to Entorhinal Cortex Lesions in Intact and Adrenalectomized Rats," J. of Neurosci. Res. 28:134-139 (1991).
Klempt et al., "Transforming Growth Factor Beta Expression in the Rat Brain is Markedly Increased After a Hypoxic-Ischemic Insult," Proc. 73rd Ann. Meeting Am. Endocrin. Soc. p. 1809 (Abstract 1991).
Logan et al., "Enhanced expression of transforming growth factor .beta.1 in the rat brain after a localized cerebral injury" Brain Res. 587:216-225 (1992).
Border et al. "Antagonists of transforming growth fctor-.beta.: A novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis," Kidney International, 41:566-570 (1992).
Shah et al. "Reduction of tissue formation in adult rodent wound healing by manipulation of the growth factor profile," J. Cell Biochem, 15 (Suppl. F):198 (Apr. 1991).
Schnell and Schwab, Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343:269-272 (1990).
Flanders et al., Transforming Growth Factor-.beta.1: Histochemical Localization with Antibodies to Different Epitopes. J. Cell Biol. 108:653-660 (1989).
Shah, M., Foreman, D.M. and Ferguson, M.W.J. Control of scarring in adult wounds by neutralising antibody to transforming growth factor .beta.. The Lancet 339:213-214 (1992).
Miller, et al., Complementary DNA Cloning of the Murine Transforming Growth Factor-.beta.3 (TGF.beta.3) Precursor and the Comparative Expression of TGF.beta.3 and TGF.beta.1 Messenger RNA in Murine Embryos and Adult Tissues. Molec. Endocrinol. 3:1926-1934 (1989).
Wilcox and Derynck, Developmental Expression of Transforming Growth Factors Alpha and Beta in Mouse Fetus. Mol. Cell. Biol. 8:3415-3422 (1988).
Edwards et al., Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO 6:1899-1904 (1987).
Laiho et al., Transforming Growth Factor-.beta. Induction of Type-1 Plasminogen Activator Inhibitor. J. Biol. Chem. 262:17467-17474 (1987).
Ignotz and Massague, Cell Adhesion Protein Receptors as Targets for Transforming Growth Factor-.beta. Action. Cell 51:189-197 (1987).
Krusius and Ruoslahti, Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. PNAS (USA) 83:7683-7687 (1986).
Baird Andrew
Logan Ann
Saoud Christine
The Whittier Institute for Diabetes and Endocrinology
Ulm John
LandOfFree
Methods of inhibiting ECM accumulation in the CNS by inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting ECM accumulation in the CNS by inhibition , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting ECM accumulation in the CNS by inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-700144